MaxCyte NASDAQ: MXCT reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue, while milestone revenue from a registrational-stage program helped offset part of the decline.The cell engineering technology company reported total revenue of $9.7 million for the quarter ended March 31, 2026, down 7% from $10.4 million in the first quarter of 2025. Core revenue was $6.2 million, down 2 ...